Changes to UK Statutory Scheme go ahead despite pharma criticism
Drug Discovery World
DECEMBER 6, 2023
It intends to set amended payment percentages for 2024 to 2026 based on an allowed growth rate that has been increased to 2%. This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% in 2024, 24% in 2025 and 26.8% While the published rates are down on the record 27.5%
Let's personalize your content